The identification of these biomarkers has assisted the development of targeted therapies that include endocrine therapy (such as tamoxifen or aromatase inhibitors) or anti-HER2 therapy (such as trastuzumab), which have considerably improved survival for women with early and relapsed breast cancer [7, 8]. Here, ERBB2 is linked to breast carcinoma.